^
    over3years
    Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway. (PubMed, Eur J Cancer)
    Palbociclib monotherapy demonstrated preliminary efficacy and an acceptable safety profile in advanced AM patients with CDK4 pathway aberrations. Patients with amplification or high protein levels of MCM7 were more prone to benefit from palbociclib. The JAK-STAT pathway might play a role in the mechanism of action of palbociclib in AM.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • JAK2 (Janus kinase 2) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • SH2B3 (SH2B Adaptor Protein 3)
    |
    JAK2 deletion
    |
    Ibrance (palbociclib)